Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial

Jens Hoeppner; Claudia Schmoor; Florian Lordick; Thomas B. Brunner; Zsolt Madarasz; Julia Michel; Stephan Voegele; Fabian Nimczewski

doi:10.1200/JCO.2026.44.16_suppl.105

Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial

Jens Hoeppner
, Claudia Schmoor
, Florian Lordick
, Thomas B. Brunner
, Zsolt Madarasz
, Julia Michel
, Stephan Voegele
, Fabian Nimczewski

Medical University Graz

Research output: Contribution to journal › Conference abstract

Original language	English
Article number	105
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	44
Issue number	16_SUPPL
DOIs	https://doi.org/10.1200/JCO.2026.44.16_suppl.105
Publication status	Published - 2026
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - McCormick Place, Chicago, United States Duration: 29 May 2026 → 2 Jun 2026

Branches of science

301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

DOI

10.1200/JCO.2026.44.16_suppl.105

Cite this

Hoeppner, J., Schmoor, C., Lordick, F., Brunner, T. B., Madarasz, Z., Michel, J., Voegele, S., & Nimczewski, F. (2026). Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial. Journal of Clinical Oncology, 44(16_SUPPL), Article 105. https://doi.org/10.1200/JCO.2026.44.16_suppl.105

@article{6c4a5b0464924f408b8a8865aa35e060,

title = "Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial",

author = "Jens Hoeppner and Claudia Schmoor and Florian Lordick and Brunner, \{Thomas B.\} and Zsolt Madarasz and Julia Michel and Stephan Voegele and Fabian Nimczewski",

year = "2026",

doi = "10.1200/JCO.2026.44.16\_suppl.105",

language = "English",

volume = "44",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "16\_SUPPL",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ASCO 2026 ; Conference date: 29-05-2026 Through 02-06-2026",

}

Hoeppner, J, Schmoor, C, Lordick, F, Brunner, TB, Madarasz, Z, Michel, J, Voegele, S & Nimczewski, F 2026, 'Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial', Journal of Clinical Oncology, vol. 44, no. 16_SUPPL, 105. https://doi.org/10.1200/JCO.2026.44.16_suppl.105

Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial. / Hoeppner, Jens; Schmoor, Claudia; Lordick, Florian et al.
In: Journal of Clinical Oncology, Vol. 44, No. 16_SUPPL, 105, 2026.

Research output: Contribution to journal › Conference abstract

TY - JOUR

T1 - Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial

AU - Hoeppner, Jens

AU - Schmoor, Claudia

AU - Lordick, Florian

AU - Brunner, Thomas B.

AU - Madarasz, Zsolt

AU - Michel, Julia

AU - Voegele, Stephan

AU - Nimczewski, Fabian

PY - 2026

Y1 - 2026

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=medunigraz_woslite&SrcAuth=WosAPI&KeyUT=WOS:001780784000001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1200/JCO.2026.44.16_suppl.105

DO - 10.1200/JCO.2026.44.16_suppl.105

M3 - Conference abstract

SN - 0732-183X

VL - 44

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16_SUPPL

M1 - 105

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 29 May 2026 through 2 June 2026

ER -

Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial

Branches of science

DOI

Links

Cite this